Wells Fargo initiated coverage on Revvity with a new price target
$RVTY
Biotechnology: Laboratory Analytical Instruments
Industrials
Wells Fargo initiated coverage of Revvity with a rating of Equal Weight and set a new price target of $95.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2025 | $115.00 | Neutral → Buy | UBS |
| 1/10/2025 | $130.00 | Outperform → Mkt Perform | Bernstein |
| 12/13/2024 | $138.00 | Neutral → Buy | BofA Securities |
| 10/15/2024 | $125.00 → $140.00 | Equal Weight → Overweight | Barclays |
| 8/28/2024 | $130.00 | Equal Weight | Wells Fargo |
| 7/8/2024 | $125.00 | Outperform | Leerink Partners |
| 6/3/2024 | $115.00 | Hold | Jefferies |
| 1/16/2024 | $105.00 → $125.00 | Buy → Neutral | UBS |
UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00
Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00
BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00